7803-65-8 Usage
Chemical Properties
white crystals
Uses
As catalyst in polyamide manufacture.
General Description
White crystalline solid. Sinks and mixes with water.
Air & Water Reactions
Water soluble. Ammonium hypophosphite liberates spontaneously flammable phosphine at about 240°C [Mellor 8:880 1946-47].
Reactivity Profile
Ammonium hypophosphite liberates spontaneously flammable phosphine at about 240°C [Mellor 8:880 1946-47]. Some inorganic materials, such as hypophosphites, tend to form explosive mixtures with perchloric acid when hot [Analyst 84:215 1959].
Hazard
Evolves flammable and toxic fumes on heating.
Health Hazard
Non-toxic or low toxicity unless heated to decomposition (240°C).
Flammability and Explosibility
Notclassified
Purification Methods
Crystallise it from hot EtOH.
Check Digit Verification of cas no
The CAS Registry Mumber 7803-65-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,8,0 and 3 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 7803-65:
(6*7)+(5*8)+(4*0)+(3*3)+(2*6)+(1*5)=108
108 % 10 = 8
So 7803-65-8 is a valid CAS Registry Number.
InChI:InChI=1/H3N.HO2P/c;1-3-2/h1H3;(H,1,2)
7803-65-8Relevant articles and documents
Syntheses, structures and magnetic properties of zig-zag chains of transition metals with O-P-O bridges
Yoshida, Yusuke,Inoue, Katsuya,Kyritsakas, Natalie,Kurmoo, Mohamedally
, p. 1428 - 1434 (2009)
A novel series of linear chain coordination polymers, [NH4][MII(H2PO2)3(H2O)] where M = Mn, Co, Ni, has been obtained by the reaction of divalent metals salts with ammonium pyrophosphite, [
SH2 domain binding inhibitors
-
Page/Page column 11, (2010/02/11)
Disclosed are compounds represented by the formula: [image] or a pharmaceutically acceptable salt or isomer thereof, wherein R1-R6 are as defined in the specification. These compounds are targeted for use as inhibitors of SH2 domain binding with a phosphoprotein, and are contemplated for use in a number of diseases including cancer. Also disclosed are pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable carrier.